The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma

Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, Roberto Sabbatini, Ugo De Giorgi, Daniele Santini, Gaetano Facchini, Alessandra Mosca, Francesco Atzori, Paolo Zucali, Giuseppe Fornarini, Francesco Massari, Sebastiano Buti, Riccardo Ricotta, Cristina Masini, Ilaria Toscani, Elisa Biasco, Annalisa Guida, Cristian Lolli, Delia De Lisi & 12 others Sabrina Rossetti, Carlo Terrone, Mario Scartozzi, Chiara Miggiano, Alessandro Pastorino, Melissa Bersanelli, Giulia Carlo-Stella, Carmine Pinto, Elisabetta Nobili, Franco Nolè, Giampaolo Tortora, Camillo Porta

Research output: Contribution to journalArticle

Abstract

We aimed to investigate the different outcomes in patients with metastatic renal cell carcinoma treated with second-line axitinib or everolimus after sunitinib. Patients treated in 16 oncological centres in Italy were included, and those receiving axitinib or everolimus from January 2013 onwards were analysed for outcomes. Descriptive statistical tests were used to highlight differences between groups. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Data on 634 patients with metastatic renal cell carcinoma treated with first-line sunitinib have been obtained. A total of 182 patients received a second-line therapy with everolimus (79 patients, 43%) or axitinib (103 patients, 57%), respectively. The median PFS was 4.6 [95% confidence (CI): 2.6-6.5] months for patients treated with everolimus and 5.5 (95% CI: 4.3-6.7) months for patients treated with axitinib (P=0.7). The median OS was 13.9 (95% CI: 10.4-17.4) months for patients treated with everolimus and 12.0 (95% CI: 7.9-16.2) months for patients treated with axitinib (P=0.3). No differences were found based on length of first-line treatment. Major limitations are the retrospective nature of the study and the lack of a prospective evaluation of the progression. This study reports no significantly differences between everolimus and axitinib in terms of both PFS and OS. Furthermore, the length of first-line treatment cannot be used as such a predictive factor and cannot suggest the use of a molecule compared with another.
Original languageEnglish
Pages (from-to)705-709
Number of pages5
JournalAnti-Cancer Drugs
Volume29
Issue number7
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Survival
Everolimus
sunitinib
axitinib
Italy
Therapeutics
Retrospective Studies

Cite this

Iacovelli, R., Cossu Rocca, M., Galli, L., Sabbatini, R., De Giorgi, U., Santini, D., ... Porta, C. (2018). The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. Anti-Cancer Drugs, 29(7), 705-709. https://doi.org/10.1097/CAD.0000000000000632

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. / Iacovelli, Roberto; Cossu Rocca, Maria; Galli, Luca; Sabbatini, Roberto; De Giorgi, Ugo; Santini, Daniele; Facchini, Gaetano; Mosca, Alessandra; Atzori, Francesco; Zucali, Paolo; Fornarini, Giuseppe; Massari, Francesco; Buti, Sebastiano; Ricotta, Riccardo; Masini, Cristina; Toscani, Ilaria; Biasco, Elisa; Guida, Annalisa; Lolli, Cristian; De Lisi, Delia; Rossetti, Sabrina; Terrone, Carlo; Scartozzi, Mario; Miggiano, Chiara; Pastorino, Alessandro; Bersanelli, Melissa; Carlo-Stella, Giulia; Pinto, Carmine; Nobili, Elisabetta; Nolè, Franco; Tortora, Giampaolo; Porta, Camillo.

In: Anti-Cancer Drugs, Vol. 29, No. 7, 01.08.2018, p. 705-709.

Research output: Contribution to journalArticle

Iacovelli, R, Cossu Rocca, M, Galli, L, Sabbatini, R, De Giorgi, U, Santini, D, Facchini, G, Mosca, A, Atzori, F, Zucali, P, Fornarini, G, Massari, F, Buti, S, Ricotta, R, Masini, C, Toscani, I, Biasco, E, Guida, A, Lolli, C, De Lisi, D, Rossetti, S, Terrone, C, Scartozzi, M, Miggiano, C, Pastorino, A, Bersanelli, M, Carlo-Stella, G, Pinto, C, Nobili, E, Nolè, F, Tortora, G & Porta, C 2018, 'The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma', Anti-Cancer Drugs, vol. 29, no. 7, pp. 705-709. https://doi.org/10.1097/CAD.0000000000000632
Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D et al. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. Anti-Cancer Drugs. 2018 Aug 1;29(7):705-709. https://doi.org/10.1097/CAD.0000000000000632
Iacovelli, Roberto ; Cossu Rocca, Maria ; Galli, Luca ; Sabbatini, Roberto ; De Giorgi, Ugo ; Santini, Daniele ; Facchini, Gaetano ; Mosca, Alessandra ; Atzori, Francesco ; Zucali, Paolo ; Fornarini, Giuseppe ; Massari, Francesco ; Buti, Sebastiano ; Ricotta, Riccardo ; Masini, Cristina ; Toscani, Ilaria ; Biasco, Elisa ; Guida, Annalisa ; Lolli, Cristian ; De Lisi, Delia ; Rossetti, Sabrina ; Terrone, Carlo ; Scartozzi, Mario ; Miggiano, Chiara ; Pastorino, Alessandro ; Bersanelli, Melissa ; Carlo-Stella, Giulia ; Pinto, Carmine ; Nobili, Elisabetta ; Nolè, Franco ; Tortora, Giampaolo ; Porta, Camillo. / The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. In: Anti-Cancer Drugs. 2018 ; Vol. 29, No. 7. pp. 705-709.
@article{4c09acca8d2143298cb601c522c59a92,
title = "The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma",
abstract = "We aimed to investigate the different outcomes in patients with metastatic renal cell carcinoma treated with second-line axitinib or everolimus after sunitinib. Patients treated in 16 oncological centres in Italy were included, and those receiving axitinib or everolimus from January 2013 onwards were analysed for outcomes. Descriptive statistical tests were used to highlight differences between groups. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Data on 634 patients with metastatic renal cell carcinoma treated with first-line sunitinib have been obtained. A total of 182 patients received a second-line therapy with everolimus (79 patients, 43{\%}) or axitinib (103 patients, 57{\%}), respectively. The median PFS was 4.6 [95{\%} confidence (CI): 2.6-6.5] months for patients treated with everolimus and 5.5 (95{\%} CI: 4.3-6.7) months for patients treated with axitinib (P=0.7). The median OS was 13.9 (95{\%} CI: 10.4-17.4) months for patients treated with everolimus and 12.0 (95{\%} CI: 7.9-16.2) months for patients treated with axitinib (P=0.3). No differences were found based on length of first-line treatment. Major limitations are the retrospective nature of the study and the lack of a prospective evaluation of the progression. This study reports no significantly differences between everolimus and axitinib in terms of both PFS and OS. Furthermore, the length of first-line treatment cannot be used as such a predictive factor and cannot suggest the use of a molecule compared with another.",
author = "Roberto Iacovelli and {Cossu Rocca}, Maria and Luca Galli and Roberto Sabbatini and {De Giorgi}, Ugo and Daniele Santini and Gaetano Facchini and Alessandra Mosca and Francesco Atzori and Paolo Zucali and Giuseppe Fornarini and Francesco Massari and Sebastiano Buti and Riccardo Ricotta and Cristina Masini and Ilaria Toscani and Elisa Biasco and Annalisa Guida and Cristian Lolli and {De Lisi}, Delia and Sabrina Rossetti and Carlo Terrone and Mario Scartozzi and Chiara Miggiano and Alessandro Pastorino and Melissa Bersanelli and Giulia Carlo-Stella and Carmine Pinto and Elisabetta Nobili and Franco Nol{\`e} and Giampaolo Tortora and Camillo Porta",
year = "2018",
month = "8",
day = "1",
doi = "10.1097/CAD.0000000000000632",
language = "English",
volume = "29",
pages = "705--709",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma

AU - Iacovelli, Roberto

AU - Cossu Rocca, Maria

AU - Galli, Luca

AU - Sabbatini, Roberto

AU - De Giorgi, Ugo

AU - Santini, Daniele

AU - Facchini, Gaetano

AU - Mosca, Alessandra

AU - Atzori, Francesco

AU - Zucali, Paolo

AU - Fornarini, Giuseppe

AU - Massari, Francesco

AU - Buti, Sebastiano

AU - Ricotta, Riccardo

AU - Masini, Cristina

AU - Toscani, Ilaria

AU - Biasco, Elisa

AU - Guida, Annalisa

AU - Lolli, Cristian

AU - De Lisi, Delia

AU - Rossetti, Sabrina

AU - Terrone, Carlo

AU - Scartozzi, Mario

AU - Miggiano, Chiara

AU - Pastorino, Alessandro

AU - Bersanelli, Melissa

AU - Carlo-Stella, Giulia

AU - Pinto, Carmine

AU - Nobili, Elisabetta

AU - Nolè, Franco

AU - Tortora, Giampaolo

AU - Porta, Camillo

PY - 2018/8/1

Y1 - 2018/8/1

N2 - We aimed to investigate the different outcomes in patients with metastatic renal cell carcinoma treated with second-line axitinib or everolimus after sunitinib. Patients treated in 16 oncological centres in Italy were included, and those receiving axitinib or everolimus from January 2013 onwards were analysed for outcomes. Descriptive statistical tests were used to highlight differences between groups. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Data on 634 patients with metastatic renal cell carcinoma treated with first-line sunitinib have been obtained. A total of 182 patients received a second-line therapy with everolimus (79 patients, 43%) or axitinib (103 patients, 57%), respectively. The median PFS was 4.6 [95% confidence (CI): 2.6-6.5] months for patients treated with everolimus and 5.5 (95% CI: 4.3-6.7) months for patients treated with axitinib (P=0.7). The median OS was 13.9 (95% CI: 10.4-17.4) months for patients treated with everolimus and 12.0 (95% CI: 7.9-16.2) months for patients treated with axitinib (P=0.3). No differences were found based on length of first-line treatment. Major limitations are the retrospective nature of the study and the lack of a prospective evaluation of the progression. This study reports no significantly differences between everolimus and axitinib in terms of both PFS and OS. Furthermore, the length of first-line treatment cannot be used as such a predictive factor and cannot suggest the use of a molecule compared with another.

AB - We aimed to investigate the different outcomes in patients with metastatic renal cell carcinoma treated with second-line axitinib or everolimus after sunitinib. Patients treated in 16 oncological centres in Italy were included, and those receiving axitinib or everolimus from January 2013 onwards were analysed for outcomes. Descriptive statistical tests were used to highlight differences between groups. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Data on 634 patients with metastatic renal cell carcinoma treated with first-line sunitinib have been obtained. A total of 182 patients received a second-line therapy with everolimus (79 patients, 43%) or axitinib (103 patients, 57%), respectively. The median PFS was 4.6 [95% confidence (CI): 2.6-6.5] months for patients treated with everolimus and 5.5 (95% CI: 4.3-6.7) months for patients treated with axitinib (P=0.7). The median OS was 13.9 (95% CI: 10.4-17.4) months for patients treated with everolimus and 12.0 (95% CI: 7.9-16.2) months for patients treated with axitinib (P=0.3). No differences were found based on length of first-line treatment. Major limitations are the retrospective nature of the study and the lack of a prospective evaluation of the progression. This study reports no significantly differences between everolimus and axitinib in terms of both PFS and OS. Furthermore, the length of first-line treatment cannot be used as such a predictive factor and cannot suggest the use of a molecule compared with another.

U2 - 10.1097/CAD.0000000000000632

DO - 10.1097/CAD.0000000000000632

M3 - Article

VL - 29

SP - 705

EP - 709

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 7

ER -